Assessing Full Benefit of Rivaroxaban Prophylaxis in High-Risk Ambulatory Patients with Cancer: Thromboembolic Events in the Randomized CASSINI Trial

Introduction In the CASSINI study, rivaroxaban thromboprophylaxis significantly reduced primary venous thromboembolism (VTE) endpoints during the intervention period, but several thromboembolic events designated as secondary efficacy endpoints were not included in the primary analysis. This study wa...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Alok A. Khorana, Mairéad G. McNamara, Ajay K. Kakkar, Michael B. Streiff, Hanno Riess, Ujjwala Vijapurkar, Simrati Kaul, Peter Wildgoose, Gerald A. Soff
Formato: Artigo
Idioma:Inglês
Publicado em: Georg Thieme Verlag KG 2020-04-01
Colecção:TH Open
Assuntos:
arterial thrombosis
cancer
thrombolysis/thrombolytic agents
thromboprophylaxis
venous thrombosis
Acesso em linha:http://www.thieme-connect.de/DOI/DOI?10.1055/s-0040-1712143
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados